パート1 · 企業の価値
概要
Hologic makes medical devices and diagnostic tests focused on women's health. It builds the mammography and biopsy systems many hospitals use for breast-cancer screening, the molecular and cytology lab equipment that runs tests for infections and cervical cancer, surgical devices used in gynecological procedures such as fibroid removal, and bone-density scanners. Most of its products are sold to hospitals, imaging centers and diagnostic labs, either directly or through distributors and group purchasing contracts.
収益の仕組み
Revenue mixes one-time capital equipment sales, such as a mammography or bone-density system, with recurring, higher-margin consumables that the equipment's installed base keeps buying: diagnostic assay cartridges, biopsy needles and single-use surgical instruments. In the US, large hospital groups buy through group purchasing organizations that negotiate on behalf of most hospitals, which caps how much pricing power any single product can hold even where the equipment locks a customer in.
セグメント別売上高
Molecular and cytology tests run on Hologic's lab instruments, covering infectious disease and cervical-cancer screening.
Mammography and breast-biopsy systems, the segment's largest source of capital-equipment revenue.
Devices for gynecological surgical procedures plus bone-density scanners, the two smallest of Hologic's business lines.
競争優位性（moat）
スイッチングコスト · 狭いA hospital that installs Hologic's Panther molecular-testing platform or its mammography systems keeps buying Hologic's matched consumables and service contracts for the equipment's life, since switching means requalifying a new system with clinicians and regulators. The advantage is narrow because Roche, BD and Siemens Healthineers sell comparable platforms and actively compete for the same equipment placements.
需要を左右する要因
ディフェンシブCancer screening, infectious-disease testing and gynecological procedures follow clinical guidelines and reimbursement coverage rather than discretionary spending, which makes underlying demand fairly steady. The more cyclical piece is capital equipment: hospitals can defer replacing a mammography system in a tight budget year even while the tests it enables keep being ordered.
主なリスク
- Reimbursement and healthcare policy risk — Sales depend on government healthcare programs and private insurers continuing to cover and reimburse Hologic's tests and procedures at workable rates; adverse coverage or guideline changes reduce market acceptance.
- Group purchasing organization pricing pressure — Group purchasing organizations negotiate on behalf of most US hospitals and can push for steep discounts, limiting how much Hologic can charge even for products with a loyal installed base.
- Concentration in two business lines — Diagnostics and Breast Health together make up roughly four-fifths of revenue, so a setback in either, such as falling COVID-era test demand, affects the company disproportionately.
- Competition from larger, diversified rivals — Hologic competes against larger, more diversified medical-technology and diagnostics companies that can outspend it on research and undercut on price in individual product categories.
強気材料
Buyers argue that women's-health screening and testing volumes are structurally growing as guidelines expand, that the installed base of mammography and molecular-diagnostics equipment keeps generating high-margin consumable sales for years, and that fiscal 2025 growth in Breast Health and GYN Surgical shows the non-COVID business is healthy on its own.
弱気材料
Sellers worry that group purchasing organizations will keep compressing per-unit pricing, that Diagnostics revenue has yet to fully offset the loss of pandemic-era test volumes, and that a portfolio this concentrated in two business lines is vulnerable to a single reimbursement or competitive setback in either one.
Written by the editors, published on 2026年8月18日
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users
Hologic's 10-K names GE HealthCare as a primary Breast Health rival: both sell 3D mammography and tomosynthesis systems to the same hospitals and imaging centres, and compete for the same installed base and service contracts.
BD is the competitor Hologic names first in cervical cancer screening: its liquid-based cytology and HPV assays go after the same clinical laboratories that buy ThinPrep and the Panther molecular platform.
Named alongside GE as Hologic's main Breast Health competitor, Siemens Healthineers sells mammography and breast biopsy systems to the same radiology departments, and also competes in laboratory diagnostics.
Through Roche Diagnostics, named in Hologic's 10-K, it sells HPV and molecular infectious-disease assays on high-throughput analysers that compete directly with Hologic's Panther system for laboratory testing volumes.
Cited in the 10-K as a full-suite surgical rival, Medtronic sells gynaecological surgery devices to the same hospitals and surgeons that Hologic targets with NovaSure and MyoSure.
利用可能な財務データが限定的です（指標の0%）。スコアはこの企業のファンダメンタルズを正確に反映していない場合があります。
貸借対照表と流動性
売上高
-
純利益
-
フリーキャッシュフロー
-
自己資本合計
-
負債合計
-
流動比率
3.75
利払い倍率
-
負債/EBITDA
-
一株当たり利益（EPS）
EPSデータがありません
売上高と純利益
損益データがありません
フリーキャッシュフロー
キャッシュフローデータがありません
収益内訳
損益データがありません
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$31.68
現在株価
-
安全マージン
-
適正価値レンジ
$30.09 - $33.26
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
31.20
ROE
11.0%
P/B レシオ
-
P/FCF
-
粗利益率
-
ROIC
-
収益性レーダー
価値創造（経済的モート）
ROIC
-
WACC
8.0%
ROIC − WACC
-
ファンダメンタル分析基準
合格（0）
不合格（0）
データなし（1）
- Error fetching data
Piotroski F-スコア
重大な財務上の懸念
利益の質
低品質：会計処理を調査してください
株式希薄化
株式を買い戻している。株主に友好的
機関投資家の保有
ガバナンス
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
Latest News
Recent headlines for HOLX, sourced from Markets Gazette.
- 4/8/2026POSITIVEHologic Goes Private In $18 Billion Blackstone, TPG Acquisition
Blackstone and TPG have successfully completed their acquisition of Hologic Inc., taking the medical technology company private in a deal valued at up to $18 billion, or $79 per share. This transaction marks a significant shift for Hologic, moving it from public trading to private ownership under the stewardship of its new private equity owners. Investors who held Hologic stock prior to the acquisition will receive the specified cash consideration, realizing a return on their investment.
via Markets Gazette